Q-omics provides the consensus-scored NDUFAF7 profile across patient tissues and cancer cell-line models. NDUFAF7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NDUFAF7 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, NDUFAF7 protein abundance shows 21,189 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, LIHC, and HNSC as cancer lineages where NDUFAF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFAF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFAF7 survival associations across molecular data types. NDUFAF7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFAF7 RNA expression–survival associations across cancer types. High NDUFAF7 expression shows unfavorable associations in ACC, LIHC, KICH, LGG, UCS and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NDUFAF7 RNA expression.
This table summarizes NDUFAF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFAF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFAF7 shows higher tumor expression in LIHC, COAD, HNSC, BLCA, LUAD and STAD. The LIHC box plot shows higher NDUFAF7 RNA expression in tumor versus normal tissue (log2 FC = +0.686, t-test p < 0.001).
This table shows molecular features associated with NDUFAF7 in patient tissues and cancer cell lines. In patient samples, NDUFAF7 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFAF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
